Previous 10 | Next 10 |
2023-05-09 19:09:06 ET Biote press release ( NASDAQ: BTMD ): Q1 GAAP EPS of -$0.39. Revenue of $44.8M (+20.8% Y/Y). Maintains FY 2023 revenue guidance of $190M-$200M vs. consensus of $193.87M. For further details see: Biote reports Q1 results, maintains F...
2023-05-09 17:56:08 ET Gainers: Upstart Holdings ( UPST ) +37% . Syneos Health ( SYNH ) +19% . LegalZoom ( LZ ) +13% . CarGurus ( CARG ) +11% . RxSight ( RXST ) +10% . Losers: Cutera ( CUTR ) -24% . TechTarget...
Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and cons...
New Initiative Targets Long-term Growth Opportunity in Men’s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the deli...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close o...
Mr. Denne to Accelerate Biote’s Expansion into Men’s Hormone Replacement Therapy Market Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company...
2023-03-28 16:22:07 ET BIOTE press release ( NASDAQ: BTMD ): Q4 GAAP EPS of $0.18 beats by $0.04 . Revenue of $44.5M (+18.7% Y/Y) beats by $0.67M . Adjusted EBITDA for the fourth quarter of 2022 was $13.1 million compared to $9.4 million for the fourth quarter ...
Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity with Recent Successful Secondary Offering Biote (NASDAQ: BTMD), a lea...
Study reports the patient also experienced “increased energy, recovery, and benefits to his sleep apnea” as well as being able to “remove supportive fracture hardware in one year” In a case study, a 54-year-old male patient with a spontaneous fracture and ost...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the 35 th Annual Roth Conference, to be held March 12-14, 2023, in ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-06 18:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 20:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz...